 Connection
Peter Crooks to Angiogenesis Inhibitors
This is a "connection" page, showing publications Peter Crooks has written about Angiogenesis Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.479 |
|
|
|
-
Howard-Sparks M, Al-Ghananeem AM, Pearson AP, Crooks PA. Evaluation of O(3alpha)-, O(21)-di-(N(1)-methyloxycarbonyl-2, 4-dioxo-5-fluoropyrimidinyl) 17alpha-hydroxy-5beta-pregnan-20-one as a novel potential antiangiogenic codrug. J Enzyme Inhib Med Chem. 2005 Oct; 20(5):417-28.
Score: 0.234
-
Venkateswaran A, Friedman DB, Walsh AJ, Skala MC, Sasi S, Rachakonda G, Crooks PA, Freeman ML, Sekhar KR. The novel antiangiogenic VJ115 inhibits the NADH oxidase ENOX1 and cytoskeleton-remodeling proteins. Invest New Drugs. 2013 Jun; 31(3):535-44.
Score: 0.095
-
Venkateswaran A, Reddy YT, Sonar VN, Muthusamy V, Crooks PA, Freeman ML, Sekhar KR. Antiangiogenic properties of substituted (Z)-(?)-2-(N-benzylindol-3-ylmethylene)quinuclidin-3-ol/one analogs and their derivatives. Bioorg Med Chem Lett. 2010 Dec 15; 20(24):7323-6.
Score: 0.083
-
Howard-Sparks M, Al-Ghananeem AM, Crooks PA, Pearson AP. A novel chemical delivery system comprising an ocular sustained release formulation of a 3alpha, 17alpha, 21-trihydroxy-5beta-pregnan-20-one-BIS-5-fluorouracil [correction of flourouracil] codrug. Drug Dev Ind Pharm. 2007 Jun; 33(6):677-82.
Score: 0.066
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|